Ansell announces zero carbon target by 2040. Picture Getty
ASX Health Stocks: Ansell commits to net zero by 2040, but says Scope 3 needs more work
Health & Biotech
share
- Ansell announces net zero commitment by 2040
- Emyria extends its library of novel MDMA-like compounds to >125
- Genetic Technologies partners with Melbourne based Siles Health
Protective personal equipment maker Ansell (ASX:ANN) has just announced ambitious new greenhouse gas (GHG) emission reduction targets, and other climate risk mitigation actions.
Ansell says it’s committing to science-based reduction targets for Scope 1 and Scope 2 that would see the company achieve net zero by 2040 for its own operations.
This target will be supported by a mid-term target of a 42% reduction in Scope 1 and Scope 2 emissions by 2030, from a FY20 baseline.
Ansell says these targets are in-line with the Paris Agreement to limit global warming to 1.5 degrees Celsius.
Over the years, Ansell has invested in initiatives to reduce its environmental impact, with these efforts being recently recognised with a silver rating by EcoVadis.
Ansell has a large and complex supply chain which represents the majority of its overall GHG emissions.
While the company admits that it has a broader ambition to reduce end-to-end value chain emissions, further engagement with its supply chain is required before it can define its Scope 3 emission reduction targets.
The new commitments announced today sit alongside the company’s previous targets to achieve zero waste to landfill at all its manufacturing operations by end of FY23.
Ansell share price today:
Other notable ASX healthcare announcements today
The digital health solutions company has secured a new contract with Yarram District Health Service.
Under the deal, GLH will provide healthcare solutions to Yarram’s hospital and community health services in Yarram, Gippsland, Victoria.
This includes the MasterCare EMR, Dashboards as a Service (DaaS), ReferralNet Secure Messaging Platform and Hothealth (Patient Engagement Platform) solutions.
This contract is GLH’s first win for FY22/23, and is approximately valued at $200,000 through the initial 12 months across implementation. It includes an annual recurring revenue (ARR) component, with an initial term of four years, with 2 x 4-year extensions.
“Our MasterCare solutions will enable Yarram to better run their day-to-day health management; provide improved reporting and business insight; actively engage with patients through an online presence and telehealth which helps to address the needs of their communities and improve patient care,” said Michael Davies, CEO of Global Health.
The biotech company and its partner, University of Western Australia (UWA), have made progress by expanding their proprietary MDMA analogue library.
19 new compounds have just been created, which brings the library size to >125 novel MDMA-like compounds.
Emyria previously secured exclusive rights to all MDMA-like compounds created under the partnership with the UWA, starting with an initial library of more than 100 novel MDMA analogues created over more than 10 years.
Emyria and UWA have been actively growing and screening this unique drug-discovery pipeline to identify new drug candidates, with the potential to address major unmet needs in mental health and neurological disorders.
Genetic Technologies (ASX:GTG)
GTG will partner with Melbourne based Siles Health, a leading obstetrics and gynaecology practice, to implement GTG’s geneType Multi-Risk Test at Siles Health’s network of clinics.
Siles Health currently operates nine clinics across Victoria, and treats over 15,000 patients annually.
The geneType Multi-Risk Test is a solution that enables an understanding of a patient’s risk of developing a range of common serious diseases.
It looks beyond inherited diseases and identifies sporadic (non inherited) risk, which can account for up to 85% of diagnosed cancers.
Over 212,4002 individuals in Australia receive a diagnosis related to one of these six diseases annually: breast cancer, colorectal cancer, ovarian cancer, coronary artery disease, prostate cancer, and type 2 diabetes.
Share prices today:
